摘要
目的探讨不同联合用药方案治疗糖尿病周围神经病变的疗效。方法选取2014年8月至2015年11月在医院就诊并住院治疗的糖尿病周围神经病变患者92例,按照随机数字表法分为对照组与观察组,各46例。两组患者均服用甲钴胺片并静脉滴注硫辛酸注射液,在此基础上,对照组患者加用卡马西平片,观察组患者加用依帕司他片。比较两组患者血糖指标、临床疗效、神经传导速度及不良反应。结果治疗后,观察组总有效率为84.78%,明显高于对照组的58.70%,差异有统计学意义(P<0.05);两组患者运动神经均有不同程度提高,观察组患者提高幅度略高于对照组,差异有统计学意义(P<0.05);两组患者血糖治疗后较本组治疗前均有明显下降(P<0.05),但组间比较差异无统计学意义(P>0.05);不良反应发生率观察组为32.61%,优于对照组的41.30%(P<0.05)。结论依帕司他较卡马西平更能缓解糖尿病周围神经病变患者的疼痛、麻木等病症,可加速患者运动神经和感觉神经的传导。
Objective To explore the efficacy of different combination regimens in the treatment of diabetic peripheral neuropathy.Methods 92 cases of diabetic peripheral neuropathy in the hospital from August 2014 to November 2015 were selected and divided into the control group and the observation group according to the random number table,46 cases in each group.The two groups were treated with mecobalamin tablets and intravenous injection of lipoic acid injection;on this basis,the control group was treated with carbamazepine tablets,and the observation group was treated with epalrestat tablets.The blood glucose,clinical efficacy,nerve conduction velocity and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the observation group was 84.78%,which was significantly higher than 58.70%of the control group,the difference was statistically significant（P〈0.05）;the motor nerve and sensory nerve conduction velocity increased in varying degrees in the two groups（P〈0.05）,and the improvement in the observation group was more than the control group（P〉0.05）.The blood glucose levels of the two groups were significantly lowered than before treatment,but the difference between the two groups had no statistical significance（P〈0.05）.The incidence of adverse reactions was 32.61%in the observation group,which was better than 41.30%in the control group（P〈0.05）.Conclusion Epalrestat is better than carbamazepine in relieving diabetic peripheral neuropathy pain and numbness symptoms.It can accelerate motor nerve and sensory nerve conduction velocity of the patients.
出处
《中国药业》
CAS
2016年第23期59-62,共4页
China Pharmaceuticals
关键词
卡马西平
依帕司他
联合用药
糖尿病周围神经病变
疗效
carbamazepine
epalrestat
combined treatment
diabetic peripheral neuropathy
efficacy
